| The Ras protein is
      activated by converting GDP to GTP.  In order to exchange GDP for GTP
      a guanine-nucleotide-exchange factor (GEF) is required to facilitate the
      transformation* (Bourne et al., 1991)   However,
      regulating the GEF is a guanine-nucleotide-dissociation inhibitor
      (GDI) which  inhibits the replacement of GDP
      to GTP in the activation process.  In the deactivation period GTP is intrinsically
      converted to GDP by GTPase activating proteins (GAP), however this process
      is mediated by GDI as well (Boguski et al., 1993).       Several members in the Ras G protein
      family have been linked to oncogenesis ( Malumbres et al.,
      1981).  Studies suggest that H-, K-, and N- Ras may be tumorigenic
      because of the inability to delocalize the GTP.  Thus, a signal is continuously
      relayed to the nucleus thereby causing increased proliferation. 
      Trends have been found linking different Ras genes to different human
      tumors.  For instance, the K-Ras is preferentially activated in the
      colon and pancreas carcinomas, H-Ras is primarily located in the bladder
      and kidney carcinomas, and the N-Ras is usually found in myeloid and
      lymphoid disorders (Bos, 1989).     | In the gene-knockout studies of Ras
            particular residues were eliminated in rats.  The
      residues 5-63, 77-92, 109-123, 139-165, and the carboxyl terminal
      sequences (Cys 186-A-X-COOH) are required for the function of Ras (Barbalid,
            M., 1987).      Recent research in rats has found that the drug
            mirthramycin may selectively bind to and inhibit the increased
            transcriptional activity associated with the tumorigenic H-Ras. 
            Mirthamycin, binds a specific G-C DNA site and thus selectively
            inhibits traniscription (Campbell et al., 1994). *The GEF is also referred to as the the
      guanine-nucleotide-releasing proteins (GNRP) or the
      guanine-nucleotide-releasing proteins (GNRP).           |